|
Submission CLI-TLC-c32d07cb
|
|
0
|
159
|
September 10, 2021
|
|
Submission MAT-POS-37ffad05
|
|
0
|
141
|
September 9, 2021
|
|
Submission MAT-POS-bf364d7a
|
|
0
|
122
|
September 8, 2021
|
|
Submission EDJ-MED-c4e42105
|
|
0
|
166
|
September 8, 2021
|
|
Submission CLI-TLC-36f34aa2
|
|
0
|
131
|
September 7, 2021
|
|
Submission CLI-TLC-3a13eaf2
|
|
0
|
137
|
September 6, 2021
|
|
Submission EDJ-MED-b2a1399d
|
|
0
|
144
|
September 6, 2021
|
|
Submission EDG-MED-9fc99cca
|
|
0
|
120
|
September 6, 2021
|
|
Submission ALP-POS-df536be7
|
|
0
|
126
|
September 6, 2021
|
|
Submission ALP-POS-d7944b10
|
|
0
|
138
|
September 6, 2021
|
|
Submission MAT-POS-e119ab4f
|
|
0
|
126
|
September 6, 2021
|
|
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
|
|
2
|
216
|
September 4, 2021
|
|
Submission MAT-POS-a54ce14d
|
|
0
|
132
|
September 2, 2021
|
|
Submission EDJ-MED-2791eece
|
|
6
|
218
|
September 2, 2021
|
|
Submission EDJ-MED-036ae2e9
|
|
0
|
126
|
September 2, 2021
|
|
Submission EDJ-MED-487c5e9f
|
|
0
|
126
|
September 2, 2021
|
|
Submission VIC-UNK-b812fd5a
|
|
0
|
160
|
September 1, 2021
|
|
Submission MAT-POS-e2d70d27
|
|
0
|
106
|
August 31, 2021
|
|
Submission DAN-MCD-93e7aadc
|
|
0
|
130
|
August 30, 2021
|
|
Submission PET-UNK-7fb4f80a
|
|
1
|
148
|
August 30, 2021
|
|
Submission JAC-UNI-14c2e728
|
|
0
|
114
|
August 29, 2021
|
|
Submission LOR-NEU-c8f11034
|
|
4
|
711
|
August 28, 2021
|
|
Submission JAC-UNI-8d446b52
|
|
0
|
140
|
August 28, 2021
|
|
Submission MAT-POS-90fd5f68
|
|
0
|
112
|
August 27, 2021
|
|
Submission DAN-MCD-cb24a79d
|
|
0
|
107
|
August 27, 2021
|
|
Submission EDJ-MED-b774e9fe
|
|
0
|
159
|
August 27, 2021
|
|
Submission EDJ-MED-43f8f7d6
|
|
0
|
134
|
August 27, 2021
|
|
Submission RAL-THA-5e0a6f1a
|
|
0
|
167
|
August 26, 2021
|
|
Submission PET-UNK-4d432d33
|
|
0
|
165
|
August 26, 2021
|
|
Submission RAL-THA-a9c31980
|
|
0
|
112
|
August 26, 2021
|